

UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN

Journal of Urology

173, 1256-1261

DOI: [10.1097/01.ju.0000155709.37840.fe](https://doi.org/10.1097/01.ju.0000155709.37840.fe)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Natural History of Clinically Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 2149.	3.8	7
2	Transrectal Sonography in Prostate Evaluation. Radiologic Clinics of North America, 2006, 44, 679-687.	0.9	28
3	Delayed surgical treatment of benign prostatic hyperplasia: a subjective estimation of change in the operative risk profile. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2006, 3, 271-278.	0.3	1
4	Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS study. Urology, 2006, 68, 804-809.	0.5	136
5	Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urology, 2006, 6, 14.	0.6	97
6	Managing enlarged prostate in primary care. International Journal of Clinical Practice, 2006, 60, 1609-1615.	0.8	8
7	The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Current Prostate Reports, 2006, 4, 81-90.	0.1	1
8	The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Current Prostate Reports, 2006, 4, 132-137.	0.1	0
9	The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the united states. Current Urology Reports, 2006, 7, 272-281.	1.0	99
10	The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Current Urology Reports, 2006, 7, 282-287.	1.0	16
11	Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases, 2006, 9, 204-214.	2.0	22
12	Metabolic Factors Associated with Benign Prostatic Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2562-2568.	1.8	281
13	Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nature Reviews Urology, 2007, 4, 155-160.	1.4	14
14	Evaluation of photoselective vaporization of the prostate. Aging Health, 2007, 3, 723-730.	0.3	0
15	Transurethral microwave thermotherapy: from evidence-based medicine to clinical practice. Current Opinion in Urology, 2007, 17, 12-16.	0.9	3
17	Five-Year Follow-up of Feedback Microwave Thermotherapy Versus TURP for Clinical BPH: A Prospective Randomized Multicenter Study. Urology, 2007, 69, 91-96.	0.5	75
18	Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?. European Urology Supplements, 2007, 6, 446-453.	0.1	7
19	A review of combination therapy in patients with benign prostatic hyperplasia. Clinical Therapeutics, 2007, 29, 387-398.	1.1	74

#	ARTICLE	IF	CITATIONS
21	In Vitro Controlled Release of Alfuzosin Hydrochloride Using HPMC-Based Matrix Tablets and Its Comparison with Marketed Product. <i>Pharmaceutical Development and Technology</i> , 2007, 12, 621-625.	1.1	38
22	Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. <i>Current Medical Research and Opinion</i> , 2007, 23, 417-426.	0.9	4
23	Kidney Cancer. <i>Journal of Urology</i> , 2007, 177, 2006-2019.	0.2	56
24	Modifiable Risk Factors for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: New Approaches to Old Problems. <i>Journal of Urology</i> , 2007, 178, 395-401.	0.2	171
25	The Efficacy of Written Screening Tools in an Inner City Hospital: Literacy Based Limitations on Patient Access to Appropriate Care. <i>Journal of Urology</i> , 2007, 178, 623-629.	0.2	31
26	Economic Evaluation of Treatment Strategies for Benign Prostatic Hyperplasia—Is Medical Therapy More Costly in the Long Run?. <i>Journal of Urology</i> , 2007, 177, 1463-1467.	0.2	13
27	Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2007, 177, 1401-1407.	0.2	339
28	Structural organization of fibrous connective tissue in the periacinar region of the transitional zone from normal human prostates as revealed by scanning electron microscopy. <i>BJU International</i> , 2007, 100, 940-944.	1.3	9
29	The effect of α -blocker and 5 α -reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. <i>BJU International</i> , 2007, 100, 853-857.	1.3	15
30	A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. <i>International Journal of Clinical Practice</i> , 2007, 61, 1535-1546.	0.8	57
31	Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. <i>International Journal of Clinical Practice</i> , 2007, 61, 1437-1445.	0.8	32
32	Minimally invasive techniques for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: An update. <i>Current Bladder Dysfunction Reports</i> , 2007, 2, 244-251.	0.2	1
33	Biomarkers for benign prostatic hyperplasia progression. <i>Current Prostate Reports</i> , 2007, 5, 121-125.	0.1	0
34	Combination 5 α -reductase inhibitors and α -blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Current Prostate Reports</i> , 2007, 5, 178-181.	0.1	0
35	Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. <i>International Urology and Nephrology</i> , 2008, 40, 921-931.	0.6	42
37	JM-27: A biomarker for symptomatic benign prostatic hyperplasia and lower urinary tract symptoms. <i>Current Prostate Reports</i> , 2008, 6, 19-23.	0.1	1
38	Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms. <i>Current Prostate Reports</i> , 2008, 6, 67-73.	0.1	34
39	Biomarkers for benign prostatic hyperplasia progression. <i>Current Urology Reports</i> , 2008, 9, 279-283.	1.0	9

#	ARTICLE	IF	CITATIONS
40	Combination 5- α -reductase inhibitors and α -blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Current Urology Reports</i> , 2008, 9, 291-294.	1.0	0
41	Simultaneous Determination of Tamsulosin and Dutasteride in Human Plasma by LC-MS/MS. <i>Chromatographia</i> , 2008, 67, 893-903.	0.7	27
42	Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment. <i>Andrologia</i> , 2008, 40, 273-281.	1.0	76
43	Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. <i>BJU International</i> , 2008, 101, 313-318.	1.3	92
44	A review of the psychosocial issues for nurses in male genitalia-related care. <i>Journal of Clinical Nursing</i> , 2008, 17, 983-998.	1.4	12
45	Chinese female nurses' perceptions of male genitalia-related care - Part 2. <i>Journal of Clinical Nursing</i> , 2009, 18, 826-837.	1.4	6
46	Physical Activity, Benign Prostatic Hyperplasia, and Lower Urinary Tract Symptoms. <i>European Urology</i> , 2008, 53, 1228-1235.	0.9	126
47	Dutasteride. <i>Drugs</i> , 2008, 68, 463-485.	4.9	44
48	Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study. <i>Journal of Urology</i> , 2008, 180, 1228-1234.	0.2	249
49	Race and Socioeconomic Status are Independently Associated With Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2008, 180, 2091-2096.	0.2	17
50	Histotripsy for the treatment of BPH: evaluation in a chronic canine model. , 2008, , .		6
51	Histotripsy: Minimally Invasive Technology for Prostatic Tissue Ablation in an In Vivo Canine Model. <i>Urology</i> , 2008, 72, 682-686.	0.5	85
52	Prevalence and Characteristics of Lower Urinary Tract Symptoms in Men Aged ≥ 80 Years. <i>Urology</i> , 2008, 72, 318-321.	0.5	128
53	A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium. <i>Journal of Urology</i> , 2008, 179, 1243-1256.	0.2	15
54	Practice Patterns in Benign Prostatic Hyperplasia Surgical Therapy: The Dramatic Increase in Minimally Invasive Technologies. <i>Journal of Urology</i> , 2008, 180, 241-245.	0.2	161
55	Patient Misunderstanding of the Individual Questions of the American Urological Association Symptom Score. <i>Journal of Urology</i> , 2008, 179, 2291-2295.	0.2	47
56	Morbidity, Mortality and Early Outcome of Transurethral Resection of the Prostate: A Prospective Multicenter Evaluation of 10,654 Patients. <i>Journal of Urology</i> , 2008, 180, 246-249.	0.2	617
57	Minimally Invasive Treatment of Male Lower Urinary Tract Symptoms. <i>Urologic Clinics of North America</i> , 2008, 35, 505-518.	0.8	7

#	ARTICLE	IF	CITATIONS
58	Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 47-52.	1.4	13
59	Benign Prostatic Hyperplasia: Health Seeking Behaviour of patients at a tertiary care hospital. <i>Australasian Medical Journal</i> , 2008, , 213-216.	0.1	0
60	Efficacy of Doxazosin in the Treatment of Acute Urinary Retention due to Benign Prostate Hyperplasia. <i>Urologia Internationalis</i> , 2008, 81, 66-71.	0.6	12
61	Effects of Running Distance and Performance on Incident Benign Prostatic Hyperplasia. <i>Medicine and Science in Sports and Exercise</i> , 2008, 40, 1733-1739.	0.2	22
62	Voiding dysfunction in men: pathophysiology and risk factors. <i>International Journal of Impotence Research</i> , 2008, 20, S2-S10.	1.0	7
63	Benign Prostatic Hyperplasia: Transcatheter Arterial Embolization as Potential Treatment—Preliminary Study in Pigs. <i>Radiology</i> , 2008, 246, 783-789.	3.6	100
64	Medical management of lower urinary tract symptoms in men: current treatment and future approaches. <i>Nature Reviews Urology</i> , 2008, 5, 211-219.	1.4	19
65	Association Between 5- α Reductase Inhibition and Risk of Hip Fracture. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1660.	3.8	40
66	Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction. <i>Current Medical Research and Opinion</i> , 2008, 24, 775-784.	0.9	19
67	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 355-365.	0.2	2
68	Androgen Regulated Genes in Human Prostate Xenografts in Mice: Relation to BPH and Prostate Cancer. <i>PLoS ONE</i> , 2009, 4, e8384.	1.1	25
69	Sildenafil: an orally active selective α 1-adrenoceptor antagonist for benign prostatic hyperplasia. <i>Aging Health</i> , 2009, 5, 459-473.	0.3	3
70	Association Between Tamsulosin and Serious Ophthalmic Adverse Events in Older Men Following Cataract Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1991.	3.8	111
71	Histotripsy of the Prostate for the Treatment of BPH: Chronic Results From a Canine Model. , 2009, , .		0
72	Four-Year Outcome of a Prospective Randomised Trial Comparing Bipolar Plasmakinetic and Monopolar Transurethral Resection of the Prostate. <i>European Urology</i> , 2009, 55, 922-931.	0.9	97
73	Editorial Comment on: Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. <i>European Urology</i> , 2009, 56, 735-736.	0.9	0
74	The value of appropriate assessment prior to specialist referral in men with prostatic symptoms. <i>Irish Journal of Medical Science</i> , 2009, 178, 281-285.	0.8	8
75	Overlap of voiding symptoms among common urologic conditions. <i>Current Bladder Dysfunction Reports</i> , 2009, 4, 176-180.	0.2	0

#	ARTICLE	IF	CITATIONS
76	Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. <i>Current Prostate Reports</i> , 2009, 7, 63-69.	0.1	3
77	Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia. <i>Current Prostate Reports</i> , 2009, 7, 117-124.	0.1	0
78	Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. <i>Current Urology Reports</i> , 2009, 10, 247-253.	1.0	26
79	Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia. <i>Current Urology Reports</i> , 2009, 10, 279-286.	1.0	11
80	Lower urinary tract symptoms increase the risk of falls in older men. <i>BJU International</i> , 2009, 104, 63-68.	1.3	152
81	Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. <i>BJU International</i> , 2009, 103, 48-57.	1.3	27
82	Scrotal Herniation of the Ureter: A Rare Late Complication After Renal Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1393-1397.	0.3	8
83	Histotripsy of the Prostate: Dose Effects in a Chronic Canine Model. <i>Urology</i> , 2009, 74, 932-937.	0.5	75
84	The Decline of TURP—An Irish Experience. <i>British Journal of Medical and Surgical Urology</i> , 2009, 2, 185-190.	0.2	1
85	<i>Lepidium meyenii</i> (Maca): A Plant from the Highlands of Peru — from Tradition to Science. <i>Research in Complementary Medicine</i> , 2009, 16, 373-380.	2.2	63
86	Diabetes and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms—What do We Know?. <i>Journal of Urology</i> , 2009, 182, S32-7.	0.2	58
87	Obesity and Benign Prostatic Hyperplasia: Clinical Connections, Emerging Etiological Paradigms and Future Directions. <i>Journal of Urology</i> , 2009, 182, S27-31.	0.2	97
88	Differences in Initial Benign Prostatic Hyperplasia Management Between Primary Care Physicians and Urologists. <i>Journal of Urology</i> , 2009, 182, 2410-2414.	0.2	18
89	Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. <i>European Urology</i> , 2009, 56, 727-736.	0.9	74
90	Alcohol Consumption is Associated With a Decreased Risk of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2009, 182, 1463-1468.	0.2	55
91	Assessment of the Performance of the American Urological Association Symptom Score in 2 Distinct Patient Populations. <i>Journal of Urology</i> , 2009, 181, 230-237.	0.2	18
92	The Demographic Burden of Urologic Diseases in America. <i>Urologic Clinics of North America</i> , 2009, 36, 11-27.	0.8	92
93	Electroresection and Open Surgery. <i>Urologic Clinics of North America</i> , 2009, 36, 461-470.	0.8	11

#	ARTICLE	IF	CITATIONS
94	Biochemical Alterations in Partial Bladder Outlet Obstruction in Mice: Up-Regulation of the Mitogen Activated Protein Kinase Pathway. <i>Journal of Urology</i> , 2009, 181, 1926-1931.	0.2	9
95	Development and External Validation of a Highly Accurate Nomogram for the Prediction of Perioperative Mortality After Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2009, 182, 626-632.	0.2	21
96	Psychosocial Predictors of Lower Urinary Tract Symptom Bother in Black Men: The Flint Men's Health Study. <i>Journal of Urology</i> , 2009, 182, 1072-1077.	0.2	7
97	Prostate histotripsy for BPH: initial canine results. <i>Proceedings of SPIE</i> , 2009, , .	0.8	0
98	Effect of Running Distance and Performance on Incident Benign Prostatic Hyperplasia. <i>Yearbook of Sports Medicine</i> , 2009, 2009, 245-247.	0.0	0
99	Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. <i>Current Bladder Dysfunction Reports</i> , 2010, 5, 212-218.	0.2	230
100	Monocyte chemoattractant protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. <i>Prostate</i> , 2010, 70, 473-481.	1.2	62
101	STEP: Simplified Treatment of the Enlarged Prostate. <i>International Journal of Clinical Practice</i> , 2010, 64, 488-496.	0.8	6
102	Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. <i>BJU International</i> , 2010, 105, 1554-1559.	1.3	47
103	Subverting Regulatory Protection of "Natural Commodities": The <i>Prunus Africana</i> in Madagascar. <i>Development and Change</i> , 2010, 41, 929-954.	2.0	10
104	Tomatoes, Tomato Products, and Lycopene in Prevention and Therapy of Prostate Diseases " Is There Evidence from Intervention Studies for Preventive and for Therapeutic Effects?. , 2010, , 343-357.		0
105	Comparison of Alfuzosin and Tamsulosin Once Daily for Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized, Prospective Study. <i>UroToday International Journal</i> , 2010, 03, .	0.1	0
106	Progression of Lower Urinary Tract Symptoms in Older Men: A Community Based Study. <i>Journal of Urology</i> , 2010, 183, 1915-1920.	0.2	60
107	Prospective Study of Serum Dihydrotestosterone and Subsequent Risk of Benign Prostatic Hyperplasia in Community Dwelling Men: The Rancho Bernardo Study. <i>Journal of Urology</i> , 2010, 184, 1040-1044.	0.2	34
108	Benign Prostatic Hyperplasia: Current Clinical Practice. <i>Primary Care - Clinics in Office Practice</i> , 2010, 37, 583-597.	0.7	18
109	Modified Suprapubic Prostatectomy Without Irrigation Is Safe. <i>Urology</i> , 2010, 75, 701-705.	0.5	11
112	Preoperative Comorbidities and Relationship of Comorbidities With Postoperative Complications in Patients Undergoing Transurethral Prostate Resection. <i>Journal of Urology</i> , 2011, 185, 1374-1378.	0.2	25
113	Effect of celecoxib on benign prostatic hyperplasia: Results of a preliminary study. <i>Urological Science</i> , 2011, 22, 147-150.	0.2	1

#	ARTICLE	IF	CITATIONS
114	Histotripsy Fractionation of Prostate Tissue: Local Effects and Systemic Response in a Canine Model. <i>Journal of Urology</i> , 2011, 185, 1484-1489.	0.2	63
116	Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2011, 185, 1793-1803.	0.2	946
117	Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial. <i>Journal of Urology</i> , 2011, 186, 965-970.	0.2	45
118	Benign Prostatic Hyperplasia Evaluation and Management by Urologists and Primary Care Physicians: Practice Patterns From the Observational BPH Registry. <i>Journal of Urology</i> , 2011, 186, 971-976.	0.2	39
119	Obesity, Physical Activity and Lower Urinary Tract Symptoms: Results From the Southern Community Cohort Study. <i>Journal of Urology</i> , 2011, 186, 2316-2322.	0.2	56
120	Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy. <i>European Urology Supplements</i> , 2011, 10, 445-450.	0.1	6
121	Hiperplasia benigna de pr ³ stata. <i>Medicine</i> , 2011, 10, 5628-5641.	0.0	0
122	Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. <i>Current Opinion in Urology</i> , 2011, 21, 1-4.	0.9	79
123	Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. <i>British Journal of General Practice</i> , 2011, 61, e684-e691.	0.7	6
124	Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. <i>BJU International</i> , 2011, 107, 1110-1116.	1.3	87
125	Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. <i>BJU International</i> , 2011, 107, 1104-1109.	1.3	40
126	Are men on 5 α -reductase inhibitors appropriately referred to urology? A survey of primary care physicians. <i>BJU International</i> , 2011, 108, 1269-1273.	1.3	4
127	Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. <i>BJU International</i> , 2011, 108, 1302-1308.	1.3	14
128	Obesity Increases and Physical Activity Decreases Lower Urinary Tract Symptom Risk in Older Men: The Osteoporotic Fractures in Men Study. <i>European Urology</i> , 2011, 60, 1173-1180.	0.9	63
129	Waist circumference is an independent risk factor for prostatic hyperplasia in Taiwanese males. <i>Asian Journal of Surgery</i> , 2011, 34, 163-167.	0.2	10
130	Association Between Socioeconomic Status (SES) and Lower Urinary Tract Symptom (LUTS) Severity Among Black and White Men. <i>Journal of General Internal Medicine</i> , 2011, 26, 1305-1310.	1.3	28
131	Post-Prostatectomy Voiding Dysfunction. <i>Current Bladder Dysfunction Reports</i> , 2011, 6, 211-217.	0.2	1
132	Recent advances in the surgical treatment of benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2011, 3, 263-272.	0.9	24

#	ARTICLE	IF	CITATIONS
133	National-wide data on the treatment of BPH in Korea. Prostate Cancer and Prostatic Diseases, 2011, 14, 243-247.	2.0	20
135	Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia. Therapeutic Advances in Urology, 2012, 4, 267-272.	0.9	5
136	American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy. Current Opinion in Urology, 2012, 22, 34-39.	0.9	26
137	Targeting Androgen Receptor to Suppress Macrophage-induced EMT and Benign Prostatic Hyperplasia (BPH) Development. Molecular Endocrinology, 2012, 26, 1707-1715.	3.7	70
138	Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients. Expert Opinion on Pharmacotherapy, 2012, 13, 2593-2600.	0.9	4
139	Changes in Initial Expenditures for Benign Prostatic Hyperplasia Evaluation in the Medicare Population: A Comparison to Overall Medicare Inflation. Journal of Urology, 2012, 187, 1739-1746.	0.2	11
140	Essential Urology. , 2012, , .		0
141	Evaluative Care Guideline Compliance Is Associated With Provision of Benign Prostatic Hyperplasia Surgery. Urology, 2012, 80, 84-89.	0.5	9
142	Urethral-sparing Histotripsy of the Prostate in a Canine Model. Urology, 2012, 80, 730-735.	0.5	20
143	Sociodemographic and lifestyle factors affecting the self-perception period of lower urinary tract symptoms of international prostate symptom score items. International Journal of Clinical Practice, 2012, 66, 1216-1223.	0.8	13
144	The Impact of Transurethral Procedures for Benign Prostate Hyperplasia on Male Sexual Function: A Meta-Analysis. Journal of Andrology, 2012, 33, 427-434.	2.0	32
146	Progression and Treatment of Incident Lower Urinary Tract Symptoms (LUTS) Among Men in the California Men'S Health Study. Annals of Epidemiology, 2012, 22, 670-671.	0.9	0
147	Prostatic Fibrosis is Associated with Lower Urinary Tract Symptoms. Journal of Urology, 2012, 188, 1375-1381.	0.2	114
148	Population Based Trends in the Surgical Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 2012, 188, 1837-1841.	0.2	32
149	Body mass index and risk of BPH: a meta-analysis. Prostate Cancer and Prostatic Diseases, 2012, 15, 265-272.	2.0	60
150	Iperplasia prostatica benigna sintomatica: ruolo degli inibitori della 5-alfa-reduttasi nella prevenzione della ritenzione urinaria acuta e degli interventi chirurgici. Italian Journal of Medicine, 2012, 6, 57-62.	0.2	0
151	Combination Pharmacological Therapies for the Management of Benign Prostatic Hyperplasia. Drugs and Aging, 2012, 29, 275-284.	1.3	15
152	Endoscopic Assessment and Prediction of Prostate Urethral Disintegration After Histotripsy Treatment in a Canine Model. Journal of Endourology, 2012, 26, 183-189.	1.1	13

#	ARTICLE	IF	CITATIONS
153	Benign Prostate Hyperplasia and Chronic Kidney Disease. , 2012, , .		2
154	Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy. Italian Journal of Medicine, 2012, , 57-62.	0.2	0
155	Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU International, 2012, 109, 84-87.	1.3	51
156	Finasteride Reduces the Risk of Incident Clinical Benign Prostatic Hyperplasia. European Urology, 2012, 62, 234-241.	0.9	50
157	Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting. BJU International, 2012, 110, 1332-1337.	1.3	9
158	Association between physical activity, lower urinary tract symptoms (<sc>LUTS</sc>) and prostate volume. BJU International, 2013, 111, 122-128.	1.3	29
159	Investigational therapies targeted to the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs, 2013, 22, 357-368.	1.9	5
160	Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis. Urologia Internationalis, 2013, 91, 10-18.	0.6	3,216
161	Association of Cadmium and Lead with Antioxidant Status and Incidence of Benign Prostatic Hyperplasia in Patients of Western India. Biological Trace Element Research, 2013, 152, 316-326.	1.9	8
162	Prostatic Artery Embolization for Enlarged Prostates Due to Benign Prostatic Hyperplasia. How I Do It. CardioVascular and Interventional Radiology, 2013, 36, 1452-1463.	0.9	87
163	Utility of Cone-Beam CT Imaging in Prostatic Artery Embolization. Journal of Vascular and Interventional Radiology, 2013, 24, 1603-1607.	0.2	100
164	The Evaluation and Treatment of Prostate-Related LUTS in the Primary Care Setting: The Next STEP. Current Urology Reports, 2013, 14, 595-605.	1.0	4
165	Risk of acute myocardial infarction after transurethral resection of prostate in elderly. BMC Surgery, 2013, 13, S35.	0.6	15
166	Propiverine. Clinical Drug Investigation, 2013, 33, 71-91.	1.1	36
167	Development and optimization of multiparticulate drug delivery system of alfuzosin hydrochloride. Colloids and Surfaces B: Biointerfaces, 2013, 102, 171-177.	2.5	13
168	Clinical Progression, Acute Urinary Retention, Prostate-Related Surgeries, and Costs in Patients with Benign Prostatic Hyperplasia Taking Early Versus Delayed Combination 5 α -Reductase Inhibitor Therapy and 1 α -Blocker Therapy: A Retrospective Analysis. Clinical Therapeutics, 2013, 35, 624-633.	1.1	10
169	Contemporary Practice Patterns of Endoscopic Surgical Management for Benign Prostatic Hyperplasia Among Urologists in the United States. Journal of Urology, 2013, 189, 1811-1816.	0.2	21
170	Androgen Receptor Roles in the Development of Benign Prostate Hyperplasia. American Journal of Pathology, 2013, 182, 1942-1949.	1.9	124

#	ARTICLE	IF	CITATIONS
171	Hyperglycemia, Hyperinsulinemia, Insulin Resistance, and the Risk of BPH/LUTS Severity and Progression Over Time in Community Dwelling Black Men: The Flint Men's Health Study. <i>Urology</i> , 2013, 82, 881-886.	0.5	10
172	1217 INTRAVESICAL PROSTATIC PROTRUSION : AS A PREDICTOR OF EARLY URINARY CONTINENCE RECOVERY AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
173	Incidence and Treatment Patterns in Males Presenting with Lower Urinary Tract Symptoms to the Emergency Department in the United States. <i>Journal of Urology</i> , 2013, 190, 1798-1804.	0.2	15
174	Differential Adoption of Laser Prostatectomy for Treatment of Benign Prostatic Hyperplasia. <i>Urology</i> , 2013, 81, 1177-1183.	0.5	10
175	The Burden of Urinary Incontinence and Urinary Bother Among Elderly Prostate Cancer Survivors. <i>European Urology</i> , 2013, 64, 672-679.	0.9	28
176	The incidence of acute urinary retention secondary to BPH is increasing among California men. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 260-265.	2.0	33
177	Obesity and Benign Prostatic Hyperplasia: Clinical Connections, Emerging Etiological Paradigms and Future Directions. <i>Journal of Urology</i> , 2013, 189, S102-6.	0.2	79
178	Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. <i>BMJ, The</i> , 2013, 346, f2109-f2109.	3.0	25
179	Effect of Phellius linteus water extract on benign prostatic hyperplasia. <i>Nutrition Research and Practice</i> , 2013, 7, 172.	0.7	13
180	Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia. <i>American Journal of Men's Health</i> , 2013, 7, 214-219.	0.7	2
181	Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia?. <i>American Journal of Epidemiology</i> , 2013, 178, 741-751.	1.6	1
182	Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. <i>International Journal of Clinical Practice</i> , 2013, 67, 606-618.	0.8	63
183	Prostatic fibrosis, lower urinary tract symptoms, and BPH. <i>Nature Reviews Urology</i> , 2013, 10, 546-550.	1.9	97
184	Alpha-1 Adrenergic Antagonists in Aircrew for the Treatment of Benign Prostatic Hypertrophy. <i>Aviation, Space, and Environmental Medicine</i> , 2013, 84, 54-58.	0.6	0
185	Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. <i>World Journal of Men's Health</i> , 2013, 31, 193.	1.7	48
186	The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses. <i>Canadian Urological Association Journal</i> , 2013, 7, E161-167.	0.3	5
187	The aging male population and medical care for benign prostatic hyperplasia in Canada. <i>Canadian Urological Association Journal</i> , 2013, 4, 123.	0.3	0
188	Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. <i>International Journal of General Medicine</i> , 2014, 7, 271.	0.8	4

#	ARTICLE	IF	CITATIONS
189	Does This Man With Lower Urinary Tract Symptoms Have Bladder Outlet Obstruction?. JAMA - Journal of the American Medical Association, 2014, 312, 535.	3.8	56
190	Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men. Prostate Cancer and Prostatic Diseases, 2014, 17, 265-272.	2.0	26
191	The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?. Turk Uroloji Dergisi, 2014, 40, 35-39.	0.4	0
192	Low Intraprostatic DHT Promotes the Infiltration of CD8+ T Cells in BPH Tissues via Modulation of CCL5 Secretion. Mediators of Inflammation, 2014, 2014, 1-9.	1.4	21
193	A green and black tea extract benefits urological health in men with lower urinary tract symptoms. Therapeutic Advances in Urology, 2014, 6, 89-96.	0.9	7
194	Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia. Medical Care, 2014, 52, 128-136.	1.1	2
195	Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. Current Opinion in Urology, 2014, 24, 10-14.	0.9	43
197	Male LUTS/BPH Made Easy. , 2014, , .		0
198	Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia. Diagnostic and Interventional Radiology, 2014, 20, 229-233.	0.7	41
199	Association of Diet With Prostate Specific Antigen and Prostate Volume. Nephro-Urology Monthly, 2014, 6, e19411.	0.0	5
200	Anesthesia for Urologic Surgery. , 2014, , .		0
201	Initial Treatment of Men With Newly Diagnosed Lower Urinary Tract Dysfunction in the Veterans Health Administration. Urology, 2014, 83, 304-311.	0.5	8
202	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. Urology, 2014, 83, 81-87.	0.5	22
203	Editorial Comment. Urology, 2014, 83, 309-310.	0.5	0
204	SIU/ICUD Consultation on Urethral Strictures: Posterior Urethral Stenosis After Treatment of Prostate Cancer. Urology, 2014, 83, S59-S70.	0.5	86
205	Ambulatory Pathway Laser Prostate Surgery in Severely Ill Patients – Feasibility and Short-term Outcomes. Urology, 2014, 83, 576-580.	0.5	4
206	Early Results from a United States Trial of Prostatic Artery Embolization in the Treatment of Benign Prostatic Hyperplasia. Journal of Vascular and Interventional Radiology, 2014, 25, 47-52.	0.2	145
207	Surgical Procedures for BPH/LUTS: Impact on Male Sexual Health. Sexual Medicine Reviews, 2014, 2, 47-55.	1.5	19

#	ARTICLE	IF	CITATIONS
208	Tadalafil - a therapeutic option in the management of BPH-LUTS. International Journal of Clinical Practice, 2014, 68, 94-103.	0.8	20
209	The Role of Prostatic Arterial Embolization in Patients with Benign Prostatic Hyperplasia: A Systematic Review. CardioVascular and Interventional Radiology, 2014, 37, 1198-1219.	0.9	43
210	Urodynamics in Male LUTS. Urologic Clinics of North America, 2014, 41, 399-407.	0.8	7
211	Lower urinary tract symptoms in men. BMJ, The, 2014, 349, g4474-g4474.	3.0	50
212	Re: Evaluation of Recent Trends in Treatment Patterns among Men with Benign Prostatic Hyperplasia. Journal of Urology, 2014, 192, 866-867.	0.2	0
213	Re: Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: Orchestrated by Chronic Prostatic Inflammation and Prostatic Calculi?. Journal of Urology, 2014, 192, 867-867.	0.2	0
214	Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5Âyears in a large population of Italian men. International Urology and Nephrology, 2014, 46, 695-701.	0.6	28
215	Society of Interventional Radiology Position Statement: Prostate Artery Embolization for Treatment of Benign Disease of the Prostate. Journal of Vascular and Interventional Radiology, 2014, 25, 1349-1351.	0.2	69
216	Dilutional hyponatremia in a community hospital setting: Case report. Intensive and Critical Care Nursing, 2014, 30, 1-5.	1.4	1
217	Prostatic Artery Embolization to Treat Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia and Bleeding in Patients with Prostate Cancer: Proceedings from a Multidisciplinary Research Consensus Panel. Journal of Vascular and Interventional Radiology, 2014, 25, 665-674.	0.2	40
218	Re: Differential Adoption of Laser Prostatectomy for Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 2014, 191, 1057-1059.	0.2	0
219	Nocturia in Older Adults. Nursing Clinics of North America, 2014, 49, 233-250.	0.7	1
220	Risk Factors for Progression or Improvement of Lower Urinary Tract Symptoms in a Prospective Cohort of Men. Journal of Urology, 2014, 191, 130-137.	0.2	76
221	Bipolar transurethral vaporization: a superior procedure in benign prostatic hyperplasia: a prospective randomized comparison with bipolar TURP. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 346-355.	0.7	19
222	Older Patient Perioperative Care as Experienced via Transurethral Resection of the Prostate (Turp). Journal of Perioperative Practice, 2014, 24, 135-140.	0.3	3
223	The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys. Scientific Reports, 2015, 5, 13546.	1.6	48
225	Inflammasomes are important mediators of prostatic inflammation associated with BPH. Journal of Inflammation, 2015, 12, 37.	1.5	40
226	Burden of benign prostatic hyperplasia among men in Japan: Patientâ€reported outcomes among those diagnosed and experiencing symptoms. International Journal of Urology, 2015, 22, 949-955.	0.5	7

#	ARTICLE	IF	CITATIONS
227	Clinical Significance of National Institutes of Health-Chronic Prostatitis Symptom Index Pain Score in Patients with Benign Prostatic Hyperplasia. <i>Urogenital Tract Infection</i> , 2015, 10, 102.	0.1	0
228	Rapid Increase of Health Care Utilization and Cost due to Benign Prostatic Hyperplasia in Korean Men: Retrospective Population-based Analysis Using the Health Insurance Review and Assessment Service Data. <i>Journal of Korean Medical Science</i> , 2015, 30, 180.	1.1	5
229	Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. <i>International Urology and Nephrology</i> , 2015, 47, 1051-1058.	0.6	8
230	Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. <i>Postgraduate Medicine</i> , 2015, 127, 301-307.	0.9	65
231	Prostatic Artery Embolization: An Emerging Technique in Interventional Radiology. <i>Journal of Radiology Nursing</i> , 2015, 34, 209-221.	0.2	3
232	Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men's Health Study. <i>BJU International</i> , 2015, 115, 127-133.	1.3	14
233	Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transperineal mapping biopsy. <i>Abdominal Imaging</i> , 2015, 40, 143-150.	2.0	6
234	Alpha-bloquants et anticholinergiques chez le sujet Ã¢gÃ©: comment prescrireÃ? <i>ProgrÃ's En Urologie - FMC</i> , 2015, 25, F9-F13.	0.2	0
235	Prostate laser vaporization is safe and effective in elderly men. <i>Urology Annals</i> , 2015, 7, 36.	0.3	11
236	Validation of a Visual Prostate Symptom Score in Men With Lower Urinary Tract Symptoms in a Health Safety Net Hospital. <i>Urology</i> , 2015, 86, 354-358.	0.5	13
237	Occlusion of the Internal Iliac Artery Is Associated with Smaller Prostate and Decreased Urinary Tract Symptoms. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1305-1310.	0.2	4
238	The effect of pomegranate fruit extract on testosterone-induced BPH in rats. <i>Prostate</i> , 2015, 75, 679-692.	1.2	38
239	Urodynamics in Male Lower Urinary Tract Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2015, 10, 125-131.	0.2	1
240	Association between self-perception period of lower urinary tract symptoms and International Prostate Symptom Score: a propensity score matching study. <i>BMC Urology</i> , 2015, 15, 30.	0.6	2
241	Transition and Lifelong Care in Congenital Urology. <i>Current Clinical Urology</i> , 2015, , .	0.0	2
242	The Diagnosis and Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia by Primary Care Family Physicians in Portugal. <i>Clinical Drug Investigation</i> , 2015, 35, 19-27.	1.1	2
243	Transurethral plasmakinetic resection of the prostate is a reliable minimal invasive technique for benign prostate hyperplasia: a meta-analysis of randomized controlled trials. <i>Asian Journal of Andrology</i> , 2015, 17, 135.	0.8	5
244	Histotripsy methods in mechanical disintegration of tissue: Towards clinical applications. <i>International Journal of Hyperthermia</i> , 2015, 31, 145-162.	1.1	216

#	ARTICLE	IF	CITATIONS
245	Lifestyle and lower urinary tract symptoms. <i>Current Opinion in Urology</i> , 2015, 25, 1-5.	0.9	19
246	New intraprostatic injectables and prostatic urethral lift for male LUTS. <i>Nature Reviews Urology</i> , 2015, 12, 461-471.	1.9	24
247	Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. <i>Therapeutic Advances in Urology</i> , 2015, 7, 249-264.	0.9	19
248	Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2015, 13, 155-161.	0.7	11
249	Stromal Androgen Receptor Roles in the Development of Normal Prostate, Benign Prostate Hyperplasia, and Prostate Cancer. <i>American Journal of Pathology</i> , 2015, 185, 293-301.	1.9	61
250	Burden of male lower urinary tract symptoms (<sc>LUTS</sc>) suggestive of benign prostatic hyperplasia (<sc>BPH</sc>) – focus on the <sc>UK</sc>. <i>BJU International</i> , 2015, 115, 508-519.	1.3	199
252	Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer. <i>Urogenital Tract Infection</i> , 2016, 11, 103.	0.1	2
253	Serum Electrolyte Disturbances in Benign Prostate Hyperplasia after Transurethral Resection of the Prostate. <i>Journal of Nephrology & Therapeutics</i> , 2016, 06, .	0.1	0
254	Severity of Lower Urinary Tract Symptoms among Middle Aged and Elderly Nigerian Men: Impact on Quality of Life. <i>Advances in Urology</i> , 2016, 2016, 1-5.	0.6	8
255	Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1311.	1.8	33
256	Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1204-1214.	0.5	6
257	Minimally Invasive Treatment Algorithm for Benign Prostatic Hyperplasia. , 2016, , 171-174.		1
258	Evaluation and Management of Lower Urinary Tract Symptoms After Outlet Surgery for Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 242-247.	0.2	4
259	Proliferation of Prostate Stromal Cell Induced by Benign Prostatic Hyperplasia Epithelial Cell Stimulated With <i>Trichomonas vaginalis</i> via Crosstalk With Mast Cell. <i>Prostate</i> , 2016, 76, 1431-1444.	1.2	31
260	New technologies in benign prostatic hyperplasia management. <i>Current Opinion in Urology</i> , 2016, 26, 254-258.	0.9	9
261	Effect of 4-chloro-7-trifluoromethyl-10 <i>H</i> -benzo[4,5]furo[3,2- <i>b</i>]indole-1-carboxylic acid on the intraurethral pressure in a rat model of benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2016, 23, 259-265.	0.5	7
262	NF- κ B and androgen receptor variant expression correlate with human BPH progression. <i>Prostate</i> , 2016, 76, 491-511.	1.2	49
263	Objective Structured Assessment of Technical Skills for the Photoselective Vaporization of the Prostate Procedure: A Pilot Study. <i>Journal of Endourology</i> , 2016, 30, 923-929.	1.1	10

#	ARTICLE	IF	CITATIONS
264	Associations between metabolic syndrome and clinical benign prostatic hyperplasia in a northern urban Han Chinese population: A prospective cohort study. <i>Scientific Reports</i> , 2016, 6, 33933.	1.6	26
265	Re: The Role of Prostatic Arterial Embolization in Patients with Benign Prostatic Hyperplasia: A Systematic Review. <i>Journal of Urology</i> , 2016, 195, 138-138.	0.2	2
266	Comparison of Holmium Laser Prostate Enucleation Outcomes in Patients with or without Preoperative Urinary Retention. <i>Journal of Urology</i> , 2016, 195, 1021-1026.	0.2	16
267	The impact of obesity towards prostate diseases. <i>Prostate International</i> , 2016, 4, 1-6.	1.2	66
268	High Rates of Inadequate Urine Volume Cause Failure of Clinic Based Uroflowmetry in Men with Lower Urinary Tract Symptoms. <i>Urology Practice</i> , 2016, 3, 247-250.	0.2	1
269	Prostate Artery Embolization as a New Treatment for Benign Prostate Hyperplasia: Contemporary Status in 2016. <i>Current Urology Reports</i> , 2016, 17, 51.	1.0	9
270	Testosterone Deficiency and the Prostate. <i>Urologic Clinics of North America</i> , 2016, 43, 203-208.	0.8	9
271	Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review. <i>Seminars in Interventional Radiology</i> , 2016, 33, 217-223.	0.3	18
272	Commercial Sponsorship and Health on the Net Certification of Online Sources of Information about Benign Prostatic Hyperplasia. <i>Urology Practice</i> , 2016, 3, 338-341.	0.2	2
273	Practical Index of Urinary Incontinence Following Holmium Laser Enucleation of the Prostate: A Case-Series Study of the 24-Hour Pad Test Immediately after Catheter Removal. <i>Urologia Internationalis</i> , 2016, 97, 310-319.	0.6	5
274	Robotic-Assisted Simple Prostatectomy. <i>Urologic Clinics of North America</i> , 2016, 43, 385-391.	0.8	12
275	The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms. <i>Urologic Clinics of North America</i> , 2016, 43, 289-297.	0.8	383
276	Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. <i>The Cochrane Library</i> , 0, , .	1.5	2
277	Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. <i>Scientific Reports</i> , 2016, 6, 23503.	1.6	37
278	Musulju improves benign prostatic hyperplasia by regulating inflammatory and apoptotic proteins. <i>Molecular Medicine Reports</i> , 2016, 14, 4692-4698.	1.1	6
279	An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 153-159.	0.2	0
280	Prostate volume growth rate changes over time: Results from men 18 to 92 years old in a longitudinal community-based study. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2016, 36, 796-800.	1.0	4
281	LUTS in pelvic ischemia: a new concept in voiding dysfunction. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F738-F743.	1.3	38

#	ARTICLE	IF	CITATIONS
282	Surgical Management of Male Voiding Dysfunction. Surgical Clinics of North America, 2016, 96, 491-501.	0.5	6
283	Evidence of the efficacy and safety of the thulium laser in the treatment of men with benign prostatic obstruction. Therapeutic Advances in Urology, 2016, 8, 181-191.	0.9	24
284	Imaging of Benign Prostatic Conditions. , 2016, , 73-81.		0
285	Oxidative stress promotes benign prostatic hyperplasia. Prostate, 2016, 76, 58-67.	1.2	69
286	Isolation and analysis of discreet human prostate cellular populations. Differentiation, 2016, 91, 139-151.	1.0	16
287	Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States. Journal of Urology, 2016, 196, 173-178.	0.2	4
288	Outcomes for prostate glands >60Âcc treated with low-dose-rate brachytherapy. Brachytherapy, 2016, 15, 163-168.	0.2	5
289	Lower Urinary Tract Symptoms and Risk of Nonspine Fractures among Older Community Dwelling U.S. Men. Journal of Urology, 2016, 196, 166-172.	0.2	11
290	Treatments for Benign Conditions of the Prostate Gland. , 2016, , 197-218.		0
291	Interventional Urology. , 2016, , .		4
292	Five-Year Follow-Up Study of Transurethral Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. Journal of Endourology, 2016, 30, 97-101.	1.1	15
293	Management of Benign Prostatic Hyperplasia. Annual Review of Medicine, 2016, 67, 137-151.	5.0	137
294	Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of mediumâ€•and largeâ€•volume prostates. BJU International, 2016, 117, 155-164.	1.3	78
295	The Informed Patient. American Journal of Men's Health, 2017, 11, 147-153.	0.7	16
296	Re: Burden of Benign Prostatic Hyperplasia among Men in Japan: Patient-Reported Outcomes among those Diagnosed and Experiencing Symptoms. Journal of Urology, 2017, 197, 772-772.	0.2	0
297	Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing theÂPrimary Care Physician and the Urologist. Urology Practice, 2017, 4, 193-199.	0.2	10
298	Surgical Options for the Enlarged, Obstructing, Benign Prostate. Journal of Urology, 2017, 197, 977-978.	0.2	2
299	CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway. Scientific Reports, 2017, 7, 42893.	1.6	28

#	ARTICLE	IF	CITATIONS
300	Continuous Positive Airway Pressure Adherence In Patients with Obstructive Sleep Apnea & Symptomatic BPH. Lung, 2017, 195, 255-261.	1.4	3
301	Reconstructive Management Options of Delayed Complications Following Bladder Outlet Surgery. Current Urology Reports, 2017, 18, 27.	1.0	0
302	The Characteristics of the Transitional Zone in Prostate Growth With Age. Urology, 2017, 105, 136-140.	0.5	11
303	Prostate Artery Embolization for Benign Prostatic Hyperplasia: Current Status. Canadian Association of Radiologists Journal, 2017, 68, 84-89.	1.1	11
304	Cost Analysis of Prostate Artery Embolization (PAE) and Transurethral Resection of the Prostate (TURP) in the Treatment of Benign Prostatic Hyperplasia. CardioVascular and Interventional Radiology, 2017, 40, 1694-1697.	0.9	47
305	Photoselective Vaporization of the Prostate Using 120 W High Performance System: A Prospective Evaluation of Results Over 2 Years. Photomedicine and Laser Surgery, 2017, 35, 300-304.	2.1	1
306	Re: Determinants of Peri-Operative Blood Transfusion in a Contemporary Series of Open Prostatectomy for Benign Prostate Hyperplasia. Journal of Urology, 2017, 197, 1323-1323.	0.2	0
307	Analysis of transrectal and suprapubic ultrasonography for prostate size evaluation. Urological Science, 2017, 28, 166-168.	0.2	3
308	How Readable Is BPH Treatment Information on the Internet? Assessing Barriers to Literacy in Prostate Health. American Journal of Men's Health, 2017, 11, 300-307.	0.7	18
309	The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Scientific Reports, 2017, 7, 7984.	1.6	126
310	Prunus africana (Hook. f.) Kalkman (the African Cherry). Medicinal and Aromatic Plants of the World, 2017, , 127-142.	0.1	1
311	Yongdamsagan-tang, a traditional herbal formula, inhibits cell growth through the suppression of proliferation and inflammation in benign prostatic hyperplasia epithelial-1 cells. Journal of Ethnopharmacology, 2017, 209, 230-235.	2.0	13
312	Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation, 2017, 96, 49-61.	1.0	48
313	Convective Radiofrequency Water Vapor Thermal Therapy with RezÅ«m System. Current Urology Reports, 2017, 18, 78.	1.0	8
314	Factors related to receipt of non-cancer-related transurethral prostatectomy: findings from a large prospective study of 106â€¦769 middle-aged and older Australian men. BMJ Open, 2017, 7, e013737.	0.8	1
315	Comparison of Perioperative Outcomes Between Holmium Laser Enucleation of the Prostate and Robot-Assisted Simple Prostatectomy. Journal of Endourology, 2017, 31, 847-850.	1.1	50
316	Changes in Weight and Metabolic Syndrome Are Associated With Prostate Growth Rate Over a 5-Year Period. Urology, 2017, 103, 185-190.	0.5	8
317	Cadaveric and radiologic study of the anatomical variations of the prostatic arteries: A review of the literature and a new classification proposal with application to prostatectomy. Clinical Anatomy, 2017, 30, 71-80.	1.5	6

#	ARTICLE	IF	CITATIONS
318	The Cardiovascular Safety of Dutasteride. <i>Journal of Urology</i> , 2017, 197, 1309-1314.	0.2	14
319	Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis. <i>Frontiers in Physiology</i> , 2017, 8, 688.	1.3	7
320	Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 29-43.	0.7	67
321	Improving access to urologists through an electronic consultation service. <i>Canadian Urological Association Journal</i> , 2017, 11, 270-4.	0.3	21
322	Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0169248.	1.1	24
323	Urological Complications of the Renal Graft. , 2017, , 573-587.		0
324	Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with RezÅ«m system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. <i>Research and Reports in Urology</i> , 2017, Volume 9, 159-168.	0.6	75
325	Epidemiology of senile prostatic enlargement among elderly men in Arar, Kingdom of Saudi Arabia. <i>Electronic Physician</i> , 2017, 9, 5349-5353.	0.2	6
326	Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2018, 200, 620-625.	0.2	8
327	Identification of reference genes and miRNAs for RT-qPCR in testosterone propionate-induced benign prostatic hyperplasia in rats. <i>Andrologia</i> , 2018, 50, e12966.	1.0	3
328	Safety and efficacy of photoselective vaporization of the prostate using the 180-W GreenLight XPS laser system in patients taking oral anticoagulants. <i>Journal of International Medical Research</i> , 2018, 46, 1230-1237.	0.4	12
329	Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention. <i>Medical Clinics of North America</i> , 2018, 102, 301-311.	1.1	19
330	Incidence and predictors of readmission within 30 days of transurethral resection of the prostate: a single center European experience. <i>Scientific Reports</i> , 2018, 8, 6575.	1.6	22
331	The Relationship between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES. <i>Journal of Urology</i> , 2018, 200, 161-166.	0.2	27
332	Relationship between lower urinary tract symptoms and cardiovascular risk scores including Framingham risk score and ACC/AHA risk score. <i>Neurourology and Urodynamics</i> , 2018, 37, 426-433.	0.8	6
333	The association of lower urinary tract symptoms with incidental falls and fear of falling in later life: The Community Health Survey. <i>Neurourology and Urodynamics</i> , 2018, 37, 775-784.	0.8	8
334	Links between lower urinary tract symptoms, intermittent hypoxia and diabetes: Causes or cures?. <i>Respiratory Physiology and Neurobiology</i> , 2018, 256, 87-96.	0.7	16
335	Efficacy and Safety of Photoselective Vaporization of the Prostate with 120 W 532â€nm Laser in Patients with Benign Prostatic Hyperplasia on Anticoagulation or Antiplatelet Therapy: Observations on Long-Term Outcomes. <i>Photomedicine and Laser Surgery</i> , 2018, 36, 273-283.	2.1	9

#	ARTICLE	IF	CITATIONS
336	Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression. <i>International Urology and Nephrology</i> , 2018, 50, 35-47.	0.6	4
337	Prostate artery embolisation: an initial experience from an Indian perspective. <i>Polish Journal of Radiology</i> , 2018, 83, 604-609.	0.5	4
339	Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature. <i>SAGE Open Nursing</i> , 2018, 4, 237796081881177.	0.5	8
340	Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong. <i>Frontiers in Pharmacology</i> , 2018, 9, 1078.	1.6	3
341	Aquablation among novice users in Canada: A WATER II subpopulation analysis. <i>Canadian Urological Association Journal</i> , 2018, 13, E113-E118.	0.3	13
342	Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men. <i>International Journal of Urology</i> , 2018, 25, 944-951.	0.5	4
343	Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia. <i>Canadian Urological Association Journal</i> , 2018, 12, .	0.3	13
344	Over-the-counter medication availability could augment self-management of male lower urinary tract symptoms. <i>Postgraduate Medicine</i> , 2018, 130, 452-460.	0.9	3
345	Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80-150cc). <i>International Journal of Impotence Research</i> , 2018, 30, 209-214.	1.0	19
346	Ten years of intraoperative floppy iris syndrome (IFIS) in the era of α -blockers. <i>Central European Journal of Urology</i> , 2018, 71, 98-104.	0.2	18
347	Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. , 2018, , 51-88.		0
348	Robotic-Assisted Laparoscopic Surgery. , 2018, , 121-130.		2
349	Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data. <i>Advances in Therapy</i> , 2018, 35, 1191-1198.	1.3	3
350	MRI features after prostatic artery embolization for the treatment of medium- and large-volume benign hyperplasia. <i>Radiologia Medica</i> , 2018, 123, 727-734.	4.7	16
351	Efficacy and safety of PDE5-Is and α -1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs. <i>BMC Urology</i> , 2018, 18, 30.	0.6	11
352	National Trend of Uroflowmetry, Urodynamic Study and Cystoscopy Considering the Change in the Population Structure in Korea from 2010 to 2015. <i>Journal of Korean Medical Science</i> , 2018, 33, e145.	1.1	8
353	Urethral stricture disease after bipolar prostatectomy: Is it a concern?. <i>African Journal of Urology</i> , 2018, 24, 24-27.	0.1	2
354	Does length of time spent on the waiting list for TURP influence the outcome?. <i>Journal of Clinical Urology</i> , 2018, 11, 184-191.	0.1	1

#	ARTICLE	IF	CITATIONS
355	The Association Between Tetrahydrocannabinol and Lower Urinary Tract Symptoms Utilizing the National Health and Nutrition Examination Survey. <i>Urology</i> , 2019, 123, 120-125.	0.5	5
356	The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea. <i>PLoS ONE</i> , 2019, 14, e0219394.	1.1	11
357	Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2019, , .	1.5	0
358	Prostate embolization: patient selection, clinical management and results. <i>CVIR Endovascular</i> , 2019, 2, 7.	0.4	13
359	Urology Residency Directors' Awareness of Association between $\hat{\pm}$ -Adrenergic Antagonists and Floppy Iris Syndrome and Practice Patterns Regarding Prophylactic $\hat{\pm}$ -Adrenergic Antagonists. <i>Journal of Academic Ophthalmology</i> (2017), 2019, 11, e7-e9.	0.2	0
360	Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis. <i>International Urology and Nephrology</i> , 2019, 51, 2127-2136.	0.6	8
361	M1 macrophage mediated increased reactive oxygen species (ROS) influence wound healing via the MAPK signaling in vitro and in vivo. <i>Toxicology and Applied Pharmacology</i> , 2019, 366, 83-95.	1.3	57
362	Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures. <i>Osteoporosis International</i> , 2019, 30, 1043-1049.	1.3	1
363	BPH: Why Do Patients Fail Medical Therapy?. <i>Current Urology Reports</i> , 2019, 20, 40.	1.0	13
364	Outcome of Botulinum Toxin $\hat{\text{A}}$ intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study. <i>Prostate</i> , 2019, 79, 1221-1225.	1.2	2
365	Functional changes in low- and high-threshold afferents in obstruction-induced bladder overactivity. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F1103-F1113.	1.3	7
366	Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse. <i>Prostate</i> , 2019, 79, 980-993.	1.2	12
367	Assessing Cost-Effectiveness of New Technologies in Stone Management. <i>Urologic Clinics of North America</i> , 2019, 46, 303-313.	0.8	16
368	Society of Interventional Radiology Multisociety Consensus Position Statement on $\hat{\text{A}}$ Prostatic Artery Embolization for Treatment of $\hat{\text{A}}$ Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Soci $\hat{\text{A}}$ t $\hat{\text{A}}$ Fran $\hat{\text{S}}$ aise de Radiologie, and the British Society of Interventional Radiology. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 627-637.e1.	0.2	80
369	A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study. <i>Urology</i> , 2019, 129, 35-42.	0.5	6
370	Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia. <i>Frontiers in Endocrinology</i> , 2019, 10, 4.	1.5	14
371	Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. <i>BMJ Open</i> , 2019, 9, e028855.	0.8	31
372	Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5919.	2.4	72

#	ARTICLE	IF	CITATIONS
373	Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. <i>Translational Andrology and Urology</i> , 2019, 8, 529-539.	0.6	118
374	Photoselective vaporization has comparative efficacy and safety among high-risk benign prostate hyperplasia patients on or off systematic anticoagulation: a meta-analysis. <i>World Journal of Urology</i> , 2019, 37, 1377-1387.	1.2	14
375	Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. <i>Aging Male</i> , 2019, 22, 12-19.	0.9	113
377	Convective Radio Frequency Thermal Therapy for Treatment of Benign Prostatic Hyperplasia: Single Office Experience with 255 Patients over 4 Years. <i>Urology Practice</i> , 2020, 7, 28-33.	0.2	3
378	Minimally Invasive Urology. , 2020, , .		0
379	Predictive value of preoperative comprehensive evaluation on the efficacy of HoLEP. <i>Translational Andrology and Urology</i> , 2020, 9, 1603-1610.	0.6	7
380	National Trends in the Management of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>Current Urology Reports</i> , 2020, 21, 63.	1.0	5
381	A Systematic Review of Reported Ejaculatory Dysfunction in Clinical Trials Evaluating Minimally Invasive Treatment Modalities for BPH. <i>Current Urology Reports</i> , 2020, 21, 54.	1.0	11
382	Efficacy, safety, and perioperative outcomes of holmium laser enucleation of the prostate—a comparison of patients with lower urinary tract symptoms and urinary retention. <i>Lasers in Medical Science</i> , 2021, 36, 1397-1402.	1.0	3
383	<sc>Co-Occurrence</sc> of Lower Urinary Tract Symptoms and Frailty among <sc>Community-Dwelling</sc> Older Men. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2805-2813.	1.3	18
384	Three-dimensional organization of the pars fibroreticularis framework of the urethral wall in normal human prostates. <i>Archives of Medical Science</i> , 2020, 16, 1057-1061.	0.4	1
385	Analyzing and Characterizing Why Men Seek Care for Lower Urinary Tract Symptoms. <i>Current Urology Reports</i> , 2020, 21, 58.	1.0	4
386	The impact of training era on the outcomes of transurethral prostatectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E465-E467.	0.3	0
387	Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: 10 Yearsâ€™ Experience. <i>Radiology</i> , 2020, 296, 444-451.	3.6	47
388	Association of Angiotensin I Converting Enzyme Insertion/287â€‰bp Deletion Polymorphisms and Proliferative Prostatic Diseases among Lebanese Men. <i>Prostate Cancer</i> , 2020, 2020, 1-6.	0.4	6
389	Spatiotemporal Proteomics Reveals the Molecular Consequences of Hormone Treatment in a Mouse Model of Lower Urinary Tract Dysfunction. <i>Journal of Proteome Research</i> , 2020, 19, 1375-1382.	1.8	5
390	Increased estrogen levels altered microRNA expression in prostate and plasma of rats dosed with sex hormones. <i>Andrology</i> , 2020, 8, 1360-1374.	1.9	9
391	Multivariate Analysis of the Failure of Removal of the Urinary Catheter within 48 Hours after Transurethral Enucleation and Resection of the Prostate. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	0

#	ARTICLE	IF	CITATIONS
392	Laser enucleation of the prostate versus transurethral resection of the prostate: perioperative outcomes from the ACS NSQIP database. <i>World Journal of Urology</i> , 2020, 38, 2891-2897.	1.2	7
393	Impact of Body Mass Index on Outcomes Following Anatomic GreenLight Laser Photoselective Vaporization of the Prostate. <i>Journal of Endourology</i> , 2021, 35, 39-45.	1.1	2
394	Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients. <i>Asian Journal of Urology</i> , 2021, 8, 289-297.	0.5	5
395	Comprehensive non-invasive analysis of lower urinary tract anatomy using MRI. <i>Abdominal Radiology</i> , 2021, 46, 1670-1676.	1.0	5
396	Misaligned Incentives in Benign Prostatic Enlargement Surgery: More Complex and Efficacious Procedures Are Earning Fewer Relative Value Units. <i>Journal of Endourology</i> , 2021, 35, 835-839.	1.1	8
397	Robotic surgery techniques to approach benign prostatic hyperplasia disease: A comprehensive literature review and the state of art. <i>Asian Journal of Urology</i> , 2021, 8, 81-88.	0.5	9
398	Association Between Lower Urinary Tract Symptoms and Frailty in Older Men Presenting for Urologic Care. <i>Urology</i> , 2021, 148, 230-234.	0.5	13
399	Efficacy and Safety of Surgery for Benign Prostatic Obstruction in Patients with Preoperative Urinary Catheter. <i>Journal of Endourology</i> , 2021, 35, 102-108.	1.1	14
400	Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia. <i>Journal of Endourology</i> , 2021, 35, 497-505.	1.1	12
401	Spectrum of urological cases in a West African Tertiary Hospital. <i>Annals of African Medicine</i> , 2021, 20, 14.	0.2	5
402	Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. <i>The Cochrane Library</i> , 2021, 2021, CD012336.	1.5	5
403	Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia. <i>BMC Urology</i> , 2021, 21, 47.	0.6	4
404	Safety and Efficacy of a Modified Technique of Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 2467.	1.3	0
405	The impact of urine microbiota in patients with lower urinary tract symptoms. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 23.	1.7	24
406	Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study. <i>Prostate</i> , 2021, 81, 478-486.	1.2	5
407	An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. <i>Asian Journal of Urology</i> , 2021, 9, 109-118.	0.5	4
408	Using prostate contrast retention (PCR) as the procedural endpoint in prostatic artery embolization for benign prostatic hyperplasia. <i>European Radiology</i> , 2021, 31, 9150-9160.	2.3	2
409	Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 830.e9-830.e16.	0.8	12

#	ARTICLE	IF	CITATIONS
410	Comparison of water vapor thermal therapy and prostate artery embolization for fragile patients with indwelling urinary catheters: Preliminary results from a multi-institutional study. <i>Progres En Urologie</i> , 2022, 32, 115-120.	0.3	9
411	Correlation of Visceral Obesity and Interleukin-6 Level on LUTS Due to Benign Prostatic Enlargement. <i>Research and Reports in Urology</i> , 2021, Volume 13, 369-373.	0.6	2
412	An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden. <i>Urology</i> , 2021, 153, 42-48.	0.5	1
413	Prolieve Transurethral Thermolab for Treatment of Symptomatic Benign Prostatic Hyperplasia: 5-Year Results from a Prospective Multicenter Trial. <i>Journal of Endourology</i> , 2022, 36, 117-123.	1.1	4
414	Monopolar Transurethral Resection of Prostate for Benign Prostatic Hyperplasia in Patients With and Without Preoperative Urinary Catheterization: A Prospective Comparative Study. <i>Cureus</i> , 2021, 13, e16705.	0.2	1
415	High regional variation in prostate surgery for benign prostatic hyperplasia in Switzerland. <i>PLoS ONE</i> , 2021, 16, e0254143.	1.1	1
416	An Approach to the Management of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.. <i>McGill Journal of Medicine</i> , 2021, 20, .	0.1	0
417	Real-world evidence with The Rezūm System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. <i>Prostate</i> , 2021, 81, 956-970.	1.2	18
418	Longitudinal Changes in Adiposity and Lower Urinary Tract Symptoms Among Older Men. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 2102-2109.	1.7	1
419	Rezūm Therapy for Benign Prostatic Hyperplasia: Dubai's Initial Experience. <i>Cureus</i> , 2021, 13, e18083.	0.2	1
420	Patient Engagement With Urologists on Social Media in a Community Practice. <i>Cureus</i> , 2021, 13, e18029.	0.2	0
421	Evaluation of the relationship between lower urinary tract symptoms and fall risks in male patients over 65 years old. <i>Journal of Gerontology and Geriatrics</i> , 0, , 1-8.	0.2	0
422	Effect of Metabolic Syndrome on Anatomy and Function of the Lower Urinary Tract Assessed on MRI. <i>Urology</i> , 2022, 159, 176-181.	0.5	1
423	Safety profile of GreenLight XPS laser photoselective vaporisation of the prostate in patients at high risk of bleeding. <i>Journal of Clinical Urology</i> , 0, , 205141582110418.	0.1	1
424	The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 416.	1.0	3
425	Efficacy of 0.4mg tamsulosin monotherapy in patients with moderate-to-severe lower urinary tract symptoms. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110473.	0.7	0
427	BPH and Pelvic Organ Prolapse in Patients with Neurogenic Bladder. <i>Current Clinical Urology</i> , 2015, , 131-139.	0.0	2
428	Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. , 2012, , 2611-2654.e8.		17

#	ARTICLE	IF	CITATIONS
429	Effects of Melandrium firmum methanolic extract on testosterone-induced benign prostatic hyperplasia in Wistar rats. <i>Asian Journal of Andrology</i> , 2012, 14, 320-324.	0.8	39
430	High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2020, 204, 325-331.	0.2	3
431	Identifying predictors of change in the severity of untreated lower urinary tract symptoms in men: a systematic review protocol. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2017, 15, 1585-1592.	1.7	5
432	CXC-Type Chemokines Promote Myofibroblast Phenoconversion and Prostatic Fibrosis. <i>PLoS ONE</i> , 2012, 7, e49278.	1.1	63
433	Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume. <i>PLoS ONE</i> , 2015, 10, e0132028.	1.1	13
434	Associations between the severity of obstructive lower urinary tract symptoms and care-seeking behavior in rural Africa: A cross-sectional survey from Uganda. <i>PLoS ONE</i> , 2017, 12, e0173631.	1.1	9
435	A pilot study of bladder voiding with real-time MRI and computational fluid dynamics. <i>PLoS ONE</i> , 2020, 15, e0238404.	1.1	15
436	Stress Urinary Incontinence post-Holmium Laser Enucleation of the Prostate: a Single-Surgeon Experience. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 624-631.	0.7	18
437	The Prevalence of Benign Prostate Hyperplasia in Korea: Using National Health Insurance Service Data. <i>Journal of Health Informatics and Statistics</i> , 2018, 43, 208-216.	0.1	7
438	Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 181-196.	0.9	9
439	The use of laser as a therapeutic modality as compared to TURP for the small prostate $\leq 40\text{ mL}$: a collaborative review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 569-575.	3.9	26
440	Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with <i>Trichomonas vaginalis</i>. <i>Korean Journal of Parasitology</i> , 2016, 54, 123-132.	0.5	19
441	Effect of <i>Celosia argentea</i> F. Cristata (L.) Schinz. on Prostate Specific Antigen, Antioxidant Status and Hematological Parameters in Rats Induced with Benign Prostate Hyperplasia. <i>Asian Journal of Biochemistry</i> , 2014, 10, 42-51.	0.5	5
442	Benign prostatic hyperplasia: Evaluation and medical management in primary care. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 53-64.	0.6	24
443	Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. <i>Indian Journal of Urology</i> , 2014, 30, 170.	0.2	150
444	Association of elderly age and chronic illnesses: Role of gender as a risk factor. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 1684.	0.3	6
445	Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience. <i>Urology Annals</i> , 2019, 11, 198.	0.3	7
446	Severe & Moderate BPH Symptoms in Mid-Aged Men Improve with Isoflavonoid-Equol Treatment: Pilot Intervention Study. <i>Open Journal of Urology</i> , 2013, 03, 21-27.	0.0	8

#	ARTICLE	IF	CITATIONS
447	Is Thulium laser enucleation of prostate an alternative to Holmium and TURP surgeries -A systematic review?. Turkish Journal of Urology, 2020, 46, 419-426.	1.3	9
448	Do Lifestyle Factors Affect Lower Urinary Tract Symptoms? Results from the Korean Community Health Survey. International Neurourology Journal, 2019, 23, 125-135.	0.5	8
449	Differential Effects of Alpha 1-Adrenoceptor Antagonists on the Postsynaptic Sensitivity: Using Slice Patch-Clamp Technique for Inhibitory Postsynaptic Current in Substantia Gelatinosa Neurons From Lumbosacral Spinal Cord in Rats. International Neurourology Journal, 2020, 24, 127-134.	0.5	2
450	Chinese Urologists' Views of Practice Patterns in the Diagnosis and Treatment of Benign Prostatic Hyperplasia: A Nationwide Survey. International Neurourology Journal, 2012, 16, 191.	0.5	5
451	Alcohol, Smoking, Physical Activity, Protein, and Lower Urinary Tract Symptoms: Prospective Longitudinal Cohort. International Neurourology Journal, 2015, 19, 197-206.	0.5	20
452	The aging male population and medical care for benign prostatic hyperplasia in Canada. Canadian Urological Association Journal, 2010, 4, 123-127.	0.3	13
453	Laser ablation of the prostate: a safe effective treatment of obstructive benign prostatic disease. Canadian Urological Association Journal, 2010, 4, 344-346.	0.3	7
454	Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial. Canadian Urological Association Journal, 2012, 6, 1-9.	0.3	9
455	Medical management of benign prostatic hyperplasia: Results from a population-based study. Canadian Urological Association Journal, 2016, 10, 55.	0.3	15
456	Standard surgical treatment for benign prostatic hyperplasia is safe for patients over 75 years: Analysis of 100 cases from a high-volume urologic center. Clinics, 2012, 67, 1415-1418.	0.6	15
457	The association of depression with lower urinary tract symptoms: data from the National Health and Nutrition Examination Survey, 2005â€“2008. PeerJ, 2019, 7, e7795.	0.9	6
458	Analyzing the quality and validity of holmium laser enucleation of prostate (HoLEP) videos on social media. Wideochirurgia I Inne Techniki Maloinwazyjne, 2022, 17, 226-231.	0.3	0
459	Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study. JMIR Formative Research, 2021, 5, e30762.	0.7	1
460	A Scoping Review of the Economic Burden of Non-Cancerous Genitourinary Conditions. Urology, 2022, 166, 29-38.	0.5	5
461	Postprostatectomy Strictures. , 2008, , 229-239.		0
463	Botulinum Toxin Injection for Prostate Disorders. , 2011, , 111-130.		0
464	Evaluation and Treatment of Male Lower Urinary Tract Symptoms. , 2012, , 243-257.		0
465	Dietary Modification of Lower Urinary Tract Symptoms with Fermented Whey Product. Open Journal of Urology, 2013, 03, 114-120.	0.0	0

#	ARTICLE	IF	CITATIONS
466	Anesthesia for Urological Endoscopic Procedures. , 2014, , 35-51.		0
468	Managing the Complex/Difficult Cases. , 2014, , 145-158.		0
469	Epidemiology and Pathophysiology of LUTS/BPO. , 2014, , 21-31.		0
470	Geriatric Urology and Aging Societies. , 2014, , 1-11.		0
472	Contribution of Diagnostic Tests and Drug Therapy in Screening of Benign Prostatic Hyperplasia (BPH) in Western Algerian Hospital. European Journal of Medicine Series B, 2014, 1, 4-9.	0.0	0
473	ANGKA KEJADIAN LUTS YANG DISEBABKAN OLEH BPH DI RSUP PROF. DR. DR. R. D. KANDOU MANADO PERIODE 2009-2013. E-CliniC, 2015, 3, .	0.1	0
474	Healthcare utilization and costs in patients with benign prostatic hyperplasia: a population-based study. Asian Journal of Andrology, 2016, 18, 942.	0.8	5
475	Transurethral bipolar prostatectomy: Where do we stand now?. World Journal of Clinical Urology, 2015, 4, 64.	0.0	0
476	Cost of illness in benign prostatic hyperplasia: A review. Society and Economy, 2015, 37, 531-542.	0.2	1
477	Benign Prostatic Hyperplasia and LUTS. , 2016, , 163-172.		0
478	Lower Urinary Tract Infections among Patients Diagnosed of Benign Prostate Hyperplasia in Federal Medical Centre, Bida, North Central, Nigeria. British Journal of Medicine and Medical Research, 2016, 14, 1-9.	0.2	1
479	Does prostate size predict the urodynamic characteristics and clinical outcomes in benign prostate hyperplasia?. Urology Annals, 2017, 9, 223.	0.3	6
480	Prostatic Monocyte Chemotactic Protein-1 (MCP-1): A Novel Potential Biomarker for Symptomatic Benign Prostatic Hyperplasia. Modern Clinical Medicine Research, 2017, 1, .	0.3	1
481	PROVIDING EMERGENCY CARE FOR ACUTE URINARY RETENTION IN MEN. MODERN MEDICAL TACTICS, CONTRADICTIONS AND PERSPECTIVES. Emergency Medical Care, 2019, 20, 69-79.	0.1	0
482	Diagnosis of Benign Prostatic Hyperplasia. , 2020, , 11-19.		2
483	Medical evaluation and management of male and female voiding dysfunction: a review. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2019, 57, 220-232.	0.3	0
484	New Alternative Treatments for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. , 2020, , 283-305.		0
485	Profile of sexuality and symptoms of lower urinary tract in non-institutionalized elderly. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 374-380.	0.7	3

#	ARTICLE	IF	CITATIONS
486	Association of Lower Urinary Tract Symptom Severity with Kidney Function among Community Dwelling Older Men. <i>Journal of Urology</i> , 2020, 204, 1305-1311.	0.2	0
487	Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. <i>Medical Science Monitor</i> , 2020, 26, e923179.	0.5	4
488	Infective Endocarditis Following TURP Procedures: A Case Report and Review of Literature. <i>American Journal of Medical Case Reports</i> , 2020, 8, 370-373.	0.1	1
489	Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia. <i>Reviews in Urology</i> , 2006, 8 Suppl 3, S9-S15.	0.9	17
490	Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. <i>P and T</i> , 2011, 36, 493-507.	1.0	8
491	Photoselective vaporization for the treatment of benign prostatic hyperplasia. <i>Ontario Health Technology Assessment Series</i> , 2013, 13, 1-34.	3.0	2
492	Stereological evaluation of fibronectin in the periurethral region of the transitional zone from normal human prostates compared with benign prostatic hyperplasia. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4143-7.	0.5	2
493	Falls in the Elderly Secondary to Urinary Symptoms. <i>Reviews in Urology</i> , 2016, 18, 28-32.	0.9	26
494	DNA methylation in development and disease: an overview for prostate researchers. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 197-218.	0.4	4
495	Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. <i>JAMA Network Open</i> , 2021, 4, e2134427.	2.8	10
496	Trends in benign prostatic hyperplasia surgery over the years: A multicenter 14-year retrospective study. , 2021, 47, 501-508.		1
497	The Impact of Illness Perceptions on Depressive Symptoms Among Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptom. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9297-9306.	0.8	1
499	The Illusory Case for Treatment of an Invented Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 682620.	1.5	4
500	Visual prostate symptom score (VPSS). Is it an effective alternative for the assessment of lower urinary tract symptoms? Experience in a reference center in southeastern Mexico. <i>Revista Mexicana De Urologia</i> , 2022, 81, 1-9.	0.0	0
501	A systematic review and meta-analysis of efficacy and safety comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for patients with prostate volume less than 100 mL or 100 g. <i>Translational Andrology and Urology</i> , 2022, 11, 407-420.	0.6	8
502	Male Lower Urinary Tract Dysfunction: An Underrepresented Endpoint in Toxicology Research. <i>Toxics</i> , 2022, 10, 89.	1.6	2
503	Oxidative Stress: A Putative Link Between Lower Urinary Tract Symptoms and Aging and Major Chronic Diseases. <i>Frontiers in Medicine</i> , 2022, 9, 812967.	1.2	5
504	The role of intraoperative void score during transurethral resection of prostate as a marker of efficacy: a feasibility study. <i>ANZ Journal of Surgery</i> , 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
505	Best nonsurgical managements of acute urinary retention: what's new?. <i>Current Opinion in Urology</i> , 2022, 32, 124-130.	0.9	8
506	Efficacy evaluation of entomological drug AdenoprosinÂ® usage in combined treatment of patients with lower urinary tract symptoms due to benign prostate enlargement. <i>Urologicheskie Vedomosti</i> , 2021, 11, 337-344.	0.4	2
507	Lower urinary tract symptoms and incident functional limitations among older communityâ€dwelling men. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1082-1094.	1.3	6
508	Longitudinal Associations between Concurrent Changes in Phenotypic Frailty and Lower Urinary Tract Symptoms among Older Men. <i>Journal of Frailty & Aging</i> , the, 0, , 1.	0.8	0
510	Human amniotic fluid stem cells can alleviate detrusor dysfunction caused by bladder outlet obstruction in rats. <i>Scientific Reports</i> , 2022, 12, 6679.	1.6	1
512	Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis. <i>BMC Urology</i> , 2022, 22, 76.	0.6	0
513	Japanese giant benign prostatic hyperplasia: Sibling cases. <i>IJU Case Reports</i> , 0, , .	0.1	0
514	Morphometric Analysis of Prostate Zonal Anatomy After Transurethral Resection of Prostate and Holmium Laser Enucleation of Prostate Using Magnetic Resonance Imaging: A Pilot Study. , 2022, 48, 201-208.		0
515	Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 113-118.	2.0	16
516	Evaluating Factors That Influence Healthcare Resource Utilization in Transurethral Resection of Prostate. <i>Journal of Endourology</i> , 0, , .	1.1	0
517	Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response. <i>Cureus</i> , 2022, , .	0.2	0
518	Numerical investigation of urethra flow characteristics in benign prostatic hyperplasia. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 224, 106978.	2.6	3
519	Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-World Settings. <i>Journal of Endourology</i> , 2023, 37, 50-59.	1.1	3
520	Evolution of healthcare costs for lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>International Urology and Nephrology</i> , 2022, 54, 2797-2803.	0.6	4
521	Benign prostatic hyperplasia is associated with increased 90-day medical complications but not peri-prosthetic joint infections following reverse shoulder arthroplasty. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 0, , .	0.6	2
522	Comparative efficacy and safety of holmium laser enucleation of the prostate (HoLEP) using moses technology and standard HoLEP: A systematic review, meta-analysis, and meta-regression. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	0.5	8
523	Differences in SUV39H1 and androgen receptor distribution in adenomyomatous hyperplasia and prostatic adenocarcinoma. <i>Nigerian Journal of Clinical Practice</i> , 2022, 25, 1387.	0.2	0
524	Defining minimal invasive surgical therapy for benign prostatic obstruction surgery: Perspectives from a global knowledge, attitude, and practice survey. <i>Asian Journal of Urology</i> , 2024, 11, 55-64.	0.5	2

#	ARTICLE	IF	CITATIONS
526	SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
527	Severe Urinary Retention Resulting in Extreme Post-obstructive Diuresis and Decompressive Hematuria. <i>Cureus</i> , 2022, , .	0.2	1
528	Possibilities and limitations of using low biomass samples for urologic disease and microbiome research. <i>Prostate International</i> , 2022, 10, 169-180.	1.2	4
529	Incidence and risk factors for postoperative urinary incontinence after various prostate enucleation procedures: systemic review and meta-analysis of PubMed literature from 2000 to 2021. <i>World Journal of Urology</i> , 2022, 40, 2731-2745.	1.2	9
530	The IL-4/IL-13 signaling axis promotes prostatic fibrosis. <i>PLoS ONE</i> , 2022, 17, e0275064.	1.1	5
531	Comparison of Cost and Perioperative Outcomes Among Patients Undergoing Simple Prostatectomy and Laser Enucleation of the Prostate. <i>Journal of Endourology</i> , 0, , .	1.1	1
532	The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>The Lancet Healthy Longevity</i> , 2022, 3, e754-e776.	2.0	32
533	Prostate gland volume estimation: anteroposterior diameters measured on axial versus sagittal ultrasonography and magnetic resonance images. <i>Ultrasonography</i> , 2023, 42, 154-164.	1.0	1
534	Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis. <i>Prostate</i> , 2023, 83, 259-267.	1.2	2
535	Endoscopic Enucleation of Prostate Could Increase Testosterone Levels in Hypotestosteronemic Patients with Bladder Outlet Obstruction. <i>Journal of Clinical Medicine</i> , 2022, 11, 6808.	1.0	1
536	Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 421-428.	2.0	15
537	Efficacy of Holmium Laser Enucleation of the Prostate in Men with Bladder Outlet Obstruction and Intravesical Prostatic Protrusion: A Functional View. , 0, , .		0
538	Assessing the readability and quality of online information about benign prostatic hyperplasia. <i>World Journal of Urology</i> , 0, , .	1.2	0
539	Transurethral water vapor therapy for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a cost-minimization and budget impact analysis from an Italian healthcare perspective. <i>Minerva Urology and Nephrology</i> , 2023, 75, .	1.3	4
540	Lower urinary tract symptom severity, urinary bother, and incident life-space mobility restriction among older men. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 1093-1104.	1.3	1
541	Benign prostatic hyperplasia treated with individualised homoeopathic medicines: An evidence-based case series. <i>Journal of Integrated Standardized Homoeopathy</i> , 0, 5, 99-106.	0.0	0
542	Sedation as an alternative anesthetic technique for frail patients in transurethral resection of the prostate. <i>Therapeutic Advances in Urology</i> , 2023, 15, 175628722211502.	0.9	0
543	Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH). <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311550.	0.8	6

#	ARTICLE	IF	CITATIONS
544	Role of circadian rhythms and melatonin in bladder function in health and diseases. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2023, 246, 103083.	1.4	6
545	Ultrasound-guided SoracteLite [®] transperineal laser ablation (TPLA) of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH): a prospective single-center experience. <i>World Journal of Urology</i> , 2023, 41, 1157-1162.	1.2	4
546	Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. <i>Advances in Clinical Medicine</i> , 2023, 13, 4208-4214.	0.0	0
547	The Lack of Standardization and Pharmacological Effect Limits the Potential Clinical Usefulness of Phytosterols in Benign Prostatic Hyperplasia. <i>Plants</i> , 2023, 12, 1722.	1.6	1
548	Enucleation of the prostate as retreatment for recurrent or residual benign prostatic obstruction: a systematic review and a meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	1
561	Navigating the Diagnostic Maze: Unraveling the Non-invasive Evaluation of Bladder Outlet Obstruction in Men—a Comprehensive Systematic Review. <i>Current Bladder Dysfunction Reports</i> , 2023, 18, 318-332.	0.2	1
564	Medical Management of Benign Prostatic Hyperplasia. , 2023, , 323-328.		0
566	BPH and Male Lower Urinary Tract Symptoms. , 2023, , 1-19.		0
569	BPH and Male Lower Urinary Tract Symptoms. , 2024, , 979-997.		0